Assessment of dd-cfDNA Levels in Clinically Stable Lung Allograft Recipients Beyond the Initial 2 y Posttransplant.
Journal
Transplantation direct
ISSN: 2373-8731
Titre abrégé: Transplant Direct
Pays: United States
ID NLM: 101651609
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
25
08
2022
revised:
26
09
2022
accepted:
27
09
2022
entrez:
21
11
2022
pubmed:
22
11
2022
medline:
22
11
2022
Statut:
epublish
Résumé
Donor-derived cell-free DNA (dd-cfDNA) is a useful biomarker for the diagnosis of acute allograft injury within the first 1 to 2 y after lung transplant, but its utility for diagnosing chronic lung allograft dysfunction (CLAD) has not yet been studied. Understanding baseline dd-cfDNA kinetics beyond the initial 2 y posttransplant is a necessary first step in determining the utility of dd-cfDNA as a CLAD biomarker. We seek to establish baseline dd-cfDNA% levels in clinically stable lung allograft recipients who are >2 y posttransplant. We performed a prospective, single-center, observational study to identify plasma dd-cfDNA levels in clinically stable lung allograft recipients >2 y posttransplant. Fifty-one subjects were enrolled and ≥3 baseline dd-cfDNA measurements were acquired during a median of 252 d. The median baseline percent dd-cfDNA level in our cohort was 0.45% (interquartile range [IQR], 0.26-0.69). There were statistically significant differences in dd-cfDNA based on posttransplant duration (≤5 y posttransplant median 0.41% [IQR, 0.21-0.64] versus >5 y posttransplant median 0.50% [IQR, 0.33-0.76]; This study is the first to define levels of dd-cfDNA in clinically stable patients who are >2 y post-lung transplant. These findings lay the groundwork for the study of dd-cfDNA as a possible biomarker for CLAD.
Identifiants
pubmed: 36406896
doi: 10.1097/TXD.0000000000001411
pmc: PMC9671749
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e1411Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL160551
Pays : United States
Informations de copyright
Copyright © 2022 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc.
Références
J Appl Lab Med. 2017 Nov 1;2(3):309-321
pubmed: 33636851
J Appl Lab Med. 2022 Jun 30;7(4):901-909
pubmed: 35024828
Curr Opin Organ Transplant. 2020 Jun;25(3):268-273
pubmed: 32332197
J Thorac Dis. 2014 Aug;6(8):1039-53
pubmed: 25132971
J Heart Lung Transplant. 2021 Aug;40(8):822-830
pubmed: 34130911
J Thorac Dis. 2017 Aug;9(8):2650-2659
pubmed: 28932572
ERJ Open Res. 2021 Jan 25;7(1):
pubmed: 33532456
ERJ Open Res. 2020 Jun 15;6(2):
pubmed: 32577419
J Heart Lung Transplant. 2017 Sep;36(9):921-933
pubmed: 28662986
Am J Respir Crit Care Med. 2018 Dec 15;198(12):e116-e136
pubmed: 30640517
Thorax. 2017 Nov;72(11):1052-1054
pubmed: 28446663
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
J Thorac Dis. 2017 Aug;9(8):2684-2691
pubmed: 28932576
Am J Transplant. 2022 Oct;22(10):2451-2457
pubmed: 35322546
Am J Transplant. 2008 Jul;8(7):1544-9
pubmed: 18557742
EBioMedicine. 2019 Feb;40:541-553
pubmed: 30692045
JAMA Surg. 2015 Mar 1;150(3):252-9
pubmed: 25629390
J Heart Lung Transplant. 2018 Jul;37(7):925-932
pubmed: 29500138
Clin Chem. 2020 Oct 1;66(10):1290-1299
pubmed: 33001185
J Heart Lung Transplant. 2020 Aug;39(8):761-770
pubmed: 32418864
Front Immunol. 2019 Jul 17;10:1681
pubmed: 31379869
J Heart Lung Transplant. 2014 Feb;33(2):127-33
pubmed: 24374027
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Transplant Direct. 2022 Mar 25;8(4):e1317
pubmed: 35372675
Biophys Rev. 2020 Aug;12(4):917-924
pubmed: 32683591